Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider David M. Chao Sells 7,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider David M. Chao sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now directly owns 225,007 shares in the company, valued at approximately $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Centessa Pharmaceuticals Trading Up 1.6 %

Shares of NASDAQ:CNTA opened at $16.77 on Thursday. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company’s 50 day moving average is $16.46 and its two-hundred day moving average is $16.36. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.21 billion, a PE ratio of -10.96 and a beta of 1.54.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $31,000. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC raised its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $171,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.